Graphenea recently announced its participation in a new project funded by EPSRC (the UK's main agency for funding research in engineering and the physical sciences). The project 2D Materials for Next Generation Healthcare Technologies (2D-Health) started on October 1 st and will utilize £5.2 million of funding over the next 5 years.
The project will aim to explore how 2D materials can assist in tackling major health challenges, such as cancer, diabetes and dementia. 2D-Health is one of four major research grants awarded as part of the EPSRC Healthcare Technologies scheme, totaling £17.7 million, that will develop new technologies to address the health issues of an aging UK population.Graphenea is one of two graphene material producers in the project consortium. Other partners include four major healthcare multinationals and laboratories from across the University of Manchester, spanning physics, chemistry, pharmacy and medicine research.
This programme directly aligns to the EPSRC Healthcare Technologies priorities by aiming to develop future therapies in specific applications of unmet clinical needs and draws on several cross-cutting capabilities:
a) custom-design 2D materials into advanced materials under specifications aimed at a precise industry-driven use, exploring different chemical modification strategies;
b) development of novel imaging and sensing technologies for tracking and monitoring therapeutic intervention; and
c) develop 2D-based technologies through the preclinical stage for each of the application areas using relevant cellular and animal models. Strong industrial-academic partnership for rapid clinical translation, in collaboration with ethicists and regulators, aims to ensure responsible and societally-acceptable innovations.